Actively Recruiting
Efficacy and Safety of the ELIOS Laser in Combined Cataract and Glaucoma Surgery
Led by Hôpital Privé de la Baie · Updated on 2026-04-01
46
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glaucoma is an irreversible optic nerve disease and the second leading cause of blindness worldwide. It can be treated with eye drops, laser, or surgery. Traditional surgery is invasive and carries risks such as hypotonia, infections, and cataracts. To reduce these risks, micro-invasive glaucoma surgeries MIGS have been developed, including the ELIOS laser system, which is specifically designed to treat glaucoma by creating tiny channels in the eyes drainage system to lower intraocular pressure IOP. This study aims to collect data on the effectiveness and safety of the ELIOS laser in combination with cataract surgery to improve patient care. Participants will undergo combined cataract and glaucoma surgery using the ELIOS laser. During the procedure, the surgeon uses the laser probe to create 10 microchannels about 210 micrometers in diameter in the trabecular meshwork and Schlemms canal to enhance fluid drainage from the eye. This micro-invasive laser procedure is performed alongside standard cataract surgery phacoemulsification and typically takes only a few minutes. The ELIOS laser is already in use in France and this study will gather prospective data on its use. Participants will be monitored regularly after surgery with measurements of intraocular pressure on day 0, day 7, day 30, and at 3, 6, and 12 months. Researchers will also assess quality of life before surgery and at 1, 3, 6, and 12 months afterward. The study will track safety and effectiveness over this one-year period to better understand outcomes for glaucoma patients receiving this combined surgery.
CONDITIONS
Brief Title
Efficacy and Safety of the ELIOS Laser in Combined Cataract and Glaucoma Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older who agree to participate and have signed informed consent
- Visually significant cataract with indication for surgery
- Primary open-angle glaucoma or secondary open-angle glaucoma (pseudoexfoliative or pigmentary) with indication for cataract surgery
- Open iridocorneal angle with Shaffer classification grade 2 to 4
- Early to moderate glaucoma with visual field mean deviation better than -12 dB
You will not qualify if you...
- Presence of severe systemic diseases
- Pregnant or breastfeeding women
- Under 18 years of age
- Other ophthalmological pathologies except cataracts, including severe dry eye
- History of intraocular surgery, trauma, or conjunctival scarring in the surgical quadrant
- Visual acuity worse than counting fingers
- Closure of the iridocorneal angle or angle-closure glaucoma and related conditions
- Normal-pressure glaucoma
- Corneal pachymetry less than 490 or greater than 620 micrometers
- Glaucomatous visual field mean deviation worse than -12 dB
- Intraocular pressure over 35 mmHg
- Autoimmune disorders, especially collagen diseases
- Patients under protective supervision
- Patients not covered by a social security scheme
Research Team
A
Ana Miguel, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here